LV10284B - Dna encoding a growth factor specific for epithelial cells - Google Patents
Dna encoding a growth factor specific for epithelial cellsInfo
- Publication number
- LV10284B LV10284B LVP-92-410A LV920410A LV10284B LV 10284 B LV10284 B LV 10284B LV 920410 A LV920410 A LV 920410A LV 10284 B LV10284 B LV 10284B
- Authority
- LV
- Latvia
- Prior art keywords
- cells
- growth factor
- protein
- kgf
- dna encoding
- Prior art date
Links
- 210000002919 epithelial cell Anatomy 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 210000003722 extracellular fluid Anatomy 0.000 abstract 1
- 102000057239 human FGF7 Human genes 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30428189A | 1989-01-31 | 1989-01-31 | |
PCT/US1990/000418 WO1990008771A1 (en) | 1989-01-31 | 1990-01-30 | Dna encoding a growth factor specific for epithelial cells |
Publications (2)
Publication Number | Publication Date |
---|---|
LV10284A LV10284A (lv) | 1994-10-20 |
LV10284B true LV10284B (en) | 1995-04-20 |
Family
ID=23175833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-92-410A LV10284B (en) | 1989-01-31 | 1992-12-23 | Dna encoding a growth factor specific for epithelial cells |
Country Status (22)
Country | Link |
---|---|
US (8) | US5707805A (de) |
EP (2) | EP0555205B1 (de) |
JP (6) | JP3298874B2 (de) |
KR (1) | KR950012805B1 (de) |
AT (1) | ATE197800T1 (de) |
AU (2) | AU647732B2 (de) |
CA (2) | CA2349875C (de) |
DE (2) | DE69033668T2 (de) |
DK (1) | DK0555205T3 (de) |
ES (1) | ES2153816T3 (de) |
FI (1) | FI114711B (de) |
GE (1) | GEP20022681B (de) |
HU (1) | HU218090B (de) |
IE (1) | IE20020188A1 (de) |
LT (1) | LT3472B (de) |
LU (1) | LU91237I2 (de) |
LV (1) | LV10284B (de) |
NL (1) | NL300230I2 (de) |
NO (2) | NO308312B1 (de) |
RU (1) | RU2250213C2 (de) |
SG (1) | SG46699A1 (de) |
WO (1) | WO1990008771A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG46699A1 (en) | 1989-01-31 | 1998-02-20 | Jeffrey S Rubin | DNA encoding a growth factor specific for epithelial cells |
GB9203533D0 (en) * | 1992-02-19 | 1992-04-08 | Erba Carlo Spa | Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies |
US5965530A (en) * | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
WO1994023032A1 (en) * | 1993-03-26 | 1994-10-13 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
BR9407035A (pt) * | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
EP0785950B1 (de) * | 1994-10-13 | 2003-04-16 | Amgen Inc., | Analogen des keratinozytenwachstumfaktors |
WO1996011950A1 (en) * | 1994-10-13 | 1996-04-25 | Amgen Inc. | Method of treating diabetes mellitus using kgf |
US6008328A (en) * | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
IL147575A (en) * | 1994-10-13 | 2004-05-12 | Amgen Inc | Method for purifying keratinocyte growth factors |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
US6077692A (en) * | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
ATE274056T1 (de) | 1995-10-11 | 2004-09-15 | Chiron Corp | Kombination pdgf, kgf, igf und igfbp zur wundheilung |
US6692961B1 (en) | 1996-10-11 | 2004-02-17 | Invitrogen Corporation | Defined systems for epithelial cell culture and use thereof |
US20030144202A1 (en) * | 1996-10-15 | 2003-07-31 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
DE19716098A1 (de) * | 1997-04-17 | 1998-10-22 | Univ Ludwigs Albert | Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden |
US6228839B1 (en) | 1997-12-19 | 2001-05-08 | Emory University | Use of keratinocyte growth factor to improve oxidative status |
CA2316015A1 (en) * | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
WO1999041282A1 (en) * | 1998-02-13 | 1999-08-19 | Human Genome Sciences, Inc. | Therapeutic uses of keratinocyte growth factor-2 |
US6335317B1 (en) | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US5929051A (en) * | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
US6313103B1 (en) | 1998-05-13 | 2001-11-06 | Carrington Laboratories, Inc. | Pectic substance as a growth factor stabilizer |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6783546B2 (en) | 1999-09-13 | 2004-08-31 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US6371984B1 (en) | 1999-09-13 | 2002-04-16 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US6395414B1 (en) | 2000-02-11 | 2002-05-28 | General Motors Corporation | Staged venting of fuel cell system during rapid shutdown |
US6376112B1 (en) | 2000-02-11 | 2002-04-23 | General Motors Corporation | Controlled shutdown of a fuel cell |
US6413662B1 (en) | 2000-02-22 | 2002-07-02 | General Motors Corporation | Fuel cell system shutdown with anode pressure control |
JP2001302691A (ja) * | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトkgfに対する抗体 |
EP1357931A2 (de) * | 2001-01-08 | 2003-11-05 | Human Genome Sciences, Inc. | Keratinozyt-wachstumsfaktor-2 |
HUP0303199A2 (hu) | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására |
US7494669B2 (en) | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
CA2457781A1 (en) * | 2001-08-21 | 2003-02-27 | Chiron Corporation | Kgf polypeptide compositions |
US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
GB0206309D0 (en) * | 2002-03-16 | 2002-05-01 | Axordia Ltd | Isolated cells |
US20050074773A1 (en) * | 2002-08-20 | 2005-04-07 | Shimkets Richard A. | Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals |
AU2005317166B2 (en) | 2004-12-15 | 2009-09-10 | Biovitrum Ab (Publ) | Therapeutic formulations of keratinocyte growth factor |
US20080119433A1 (en) * | 2006-07-06 | 2008-05-22 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
PL2125878T3 (pl) * | 2007-01-05 | 2013-08-30 | Helix Biomedix Inc | Krótkie, aktywne biologicznie peptydy do komórkowych i immunologicznych modulacji |
WO2011008904A1 (en) | 2009-07-17 | 2011-01-20 | Tabor Aaron T | Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
US9682093B2 (en) | 2012-03-30 | 2017-06-20 | Charles R. Drew University Of Medicine And Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
KR102277147B1 (ko) * | 2017-12-13 | 2021-07-13 | 건국대학교 산학협력단 | 섬유아 성장인자 유래 펩타이드의 골 또는 연골 분화 촉진 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5096825A (en) * | 1983-01-12 | 1992-03-17 | Chiron Corporation | Gene for human epidermal growth factor and synthesis and expression thereof |
US4444760A (en) * | 1983-06-17 | 1984-04-24 | Merck & Co., Inc. | Purification and characterization of a protein fibroblast growth factor |
US4473679A (en) | 1983-12-12 | 1984-09-25 | Borg-Warner Chemicals, Inc. | Thermoplastic acrylic elastomers |
US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
US4868113A (en) | 1986-03-03 | 1989-09-19 | Rorer Biotechnology, Inc. | Recombinant DNA vector encoding human endothelial cell growth factor |
US4983679A (en) | 1986-05-29 | 1991-01-08 | E. I. Dupont De Nemours And Company | β-(keto or sulfonyl)esters from reaction of silylketene acetal and acyl or sulfonyl compound |
HU219883B (hu) | 1988-03-17 | 2001-08-28 | Novo-Nordisk A/S | Heparinkötő proteinek, ezeket kódoló DNS és a proteineket tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására |
SG46699A1 (en) | 1989-01-31 | 1998-02-20 | Jeffrey S Rubin | DNA encoding a growth factor specific for epithelial cells |
BR9407035A (pt) * | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
WO1996011950A1 (en) | 1994-10-13 | 1996-04-25 | Amgen Inc. | Method of treating diabetes mellitus using kgf |
-
1990
- 1990-01-30 SG SG1996008633A patent/SG46699A1/en unknown
- 1990-01-30 GE GEAP1990983A patent/GEP20022681B/en unknown
- 1990-01-30 EP EP90903253A patent/EP0555205B1/de not_active Expired - Lifetime
- 1990-01-30 AT AT90903253T patent/ATE197800T1/de active
- 1990-01-30 RU SU5001740/13A patent/RU2250213C2/ru active
- 1990-01-30 AU AU50496/90A patent/AU647732B2/en not_active Expired
- 1990-01-30 ES ES90903253T patent/ES2153816T3/es not_active Expired - Lifetime
- 1990-01-30 DK DK90903253T patent/DK0555205T3/da active
- 1990-01-30 WO PCT/US1990/000418 patent/WO1990008771A1/en active IP Right Grant
- 1990-01-30 EP EP00103140A patent/EP1016716A3/de not_active Withdrawn
- 1990-01-30 HU HU998/90A patent/HU218090B/hu unknown
- 1990-01-30 JP JP50341390A patent/JP3298874B2/ja not_active Expired - Lifetime
- 1990-01-30 DE DE69033668T patent/DE69033668T2/de not_active Expired - Lifetime
- 1990-01-31 IE IE20020188A patent/IE20020188A1/en not_active Application Discontinuation
- 1990-09-29 KR KR90702202A patent/KR950012805B1/ko not_active IP Right Cessation
-
1991
- 1991-03-15 CA CA2349875A patent/CA2349875C/en not_active Expired - Lifetime
- 1991-03-15 CA CA002038398A patent/CA2038398C/en not_active Expired - Lifetime
- 1991-07-30 FI FI913637A patent/FI114711B/fi active
-
1992
- 1992-12-23 LV LVP-92-410A patent/LV10284B/xx unknown
-
1993
- 1993-06-21 LT LTIP667A patent/LT3472B/lt not_active IP Right Cessation
-
1994
- 1994-06-28 AU AU65986/94A patent/AU684278B2/en not_active Expired
-
1995
- 1995-05-31 US US08/455,641 patent/US5707805A/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,620 patent/US6420531B1/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,628 patent/US5665870A/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,655 patent/US5654405A/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,975 patent/US6833132B1/en not_active Expired - Lifetime
- 1995-05-31 US US08/455,672 patent/US5741642A/en not_active Expired - Lifetime
- 1995-06-07 US US08/477,982 patent/US6709842B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,948 patent/US5731170A/en not_active Expired - Lifetime
- 1995-12-27 JP JP7341890A patent/JP2716416B2/ja not_active Expired - Lifetime
-
1997
- 1997-05-16 NO NO972259A patent/NO308312B1/no not_active IP Right Cessation
- 1997-06-06 NO NO972617A patent/NO308310B1/no not_active IP Right Cessation
- 1997-10-22 JP JP09290175A patent/JP3088983B2/ja not_active Expired - Lifetime
-
1999
- 1999-10-06 JP JP28551799A patent/JP3802292B2/ja not_active Expired - Lifetime
-
2000
- 2000-10-11 JP JP2000311208A patent/JP3802329B2/ja not_active Expired - Lifetime
-
2006
- 2006-03-06 JP JP2006060217A patent/JP2006149407A/ja not_active Withdrawn
- 2006-04-11 DE DE200612000021 patent/DE122006000021I1/de active Pending
- 2006-04-19 NL NL300230C patent/NL300230I2/nl unknown
- 2006-04-24 LU LU91237C patent/LU91237I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950012805B1 (en) | Dna encoding a growth factor specific for epitheliad cells | |
IE820069L (en) | Recombinant dna encoding a polypeptide | |
MY137300A (en) | Chimeric proteins for use in transport of a selected substance into cells | |
NO963371L (no) | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det | |
AU7532887A (en) | Diagnosis method for detection of b-cell neoplasms | |
IL87255A (en) | Dna constructs containing a kluyveromycesalpha- factorleader sequence for directingsecretion of heterologouspolypeptides | |
ATE49233T1 (de) | Vektoren zur transformation von hefe. | |
DE69132530D1 (de) | Heparin bindendes mitogen mit homologie zum epidermis wachstumsfaktor (egf) | |
ATE135371T1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
HUP0002472A2 (hu) | Izolált dendritikus sejtmembrán-fehérje gének | |
JPS6420095A (en) | Polypeptide having anti-blood coagulating action | |
WO1992007939A3 (en) | Polypeptide with 46kd hmfg differentiation antigen binding specificity | |
GB2171703B (en) | Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re | |
EP0286147A3 (de) | Insulin-bindende Peptide und deren Verwendung | |
DE69932644D1 (de) | Menschliches Protein mit in vitro antiproliferativer Aktivität. |